Literature DB >> 19642168

De novo bile salt transporter antibodies as a possible cause of recurrent graft failure after liver transplantation: a novel mechanism of cholestasis.

Verena Keitel1, Martin Burdelski, Zsuzsanna Vojnisek, Lutz Schmitt, Dieter Häussinger, Ralf Kubitz.   

Abstract

Progressive familial intrahepatic cholestasis type 2 (PFIC-2) is caused by mutations of the bile salt export pump (BSEP [ABCB11]), an ATP-binding cassette (ABC)-transporter exclusively expressed at the canalicular membrane of hepatocytes. An absence of BSEP from the canalicular membrane causes cholestasis and leads to liver cirrhosis, which may necessitate liver transplantation in early childhood. We report on the first case of a child with PFIC-2 suffering from repeated posttransplant recurrence of progressive intrahepatic cholestasis due to autoantibodies against BSEP. These antibodies occurred after transplantation and were detected in the patient's serum and at the canalicular membrane of two consecutive liver transplants. The antibodies were reactive toward the first extracellular loop of BSEP, were of high affinity, and inhibited transport activity of BSEP, thus causing severe cholestasis. The patient had three homozygous, missense changes in the BSEP gene. Their combination resulted in the complete absence of BSEP, which explains the lack of tolerance, a prerequisite of autoantibody formation toward BSEP. The findings illustrate a novel disease mechanism due to a new class of functionally relevant autoantibodies resulting in cholestasis and subsequent liver failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19642168     DOI: 10.1002/hep.23083

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Clinical utility gene card for: progressive familial intrahepatic cholestasis type 2.

Authors:  Emmanuel Gonzales; Anne Spraul; Emmanuel Jacquemin
Journal:  Eur J Hum Genet       Date:  2013-08-28       Impact factor: 4.246

Review 2.  Liver transplantation and the management of progressive familial intrahepatic cholestasis in children.

Authors:  Ashley Mehl; Humberto Bohorquez; Maria-Stella Serrano; Gretchen Galliano; Trevor W Reichman
Journal:  World J Transplant       Date:  2016-06-24

Review 3.  Autoimmune BSEP disease: disease recurrence after liver transplantation for progressive familial intrahepatic cholestasis.

Authors:  Ralf Kubitz; Carola Dröge; Stefanie Kluge; Claudia Stross; Nathalie Walter; Verena Keitel; Dieter Häussinger; Jan Stindt
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 4.  Cholestatic liver disease in children.

Authors:  Jorge L Santos; Monique Choquette; Jorge A Bezerra
Journal:  Curr Gastroenterol Rep       Date:  2010-02

Review 5.  Gene replacement therapy for genetic hepatocellular jaundice.

Authors:  Remco van Dijk; Ulrich Beuers; Piter J Bosma
Journal:  Clin Rev Allergy Immunol       Date:  2015-06       Impact factor: 8.667

Review 6.  Biosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.

Authors:  Carol J Soroka; James L Boyer
Journal:  Mol Aspects Med       Date:  2013-05-15

Review 7.  Bile formation and secretion.

Authors:  James L Boyer
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

Review 8.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

9.  High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.

Authors:  Tadahiro Shinozawa; Masaki Kimura; Yuqi Cai; Norikazu Saiki; Yosuke Yoneyama; Rie Ouchi; Hiroyuki Koike; Mari Maezawa; Ran-Ran Zhang; Andrew Dunn; Autumn Ferguson; Shodai Togo; Kyle Lewis; Wendy L Thompson; Akihiro Asai; Takanori Takebe
Journal:  Gastroenterology       Date:  2020-10-08       Impact factor: 22.682

10.  Heterologous overexpression and mutagenesis of the human bile salt export pump (ABCB11) using DREAM (Directed REcombination-Assisted Mutagenesis).

Authors:  Jan Stindt; Philipp Ellinger; Claudia Stross; Verena Keitel; Dieter Häussinger; Sander H J Smits; Ralf Kubitz; Lutz Schmitt
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.